Literature DB >> 8528883

Competitive reverse transcriptase-polymerase chain reaction using a synthetic internal RNA standard to quantitate transcripts for leukocyte-derived hormones.

Q Liu1, S Arkins, A Biragyn, C Minshall, P Parnet, R Dantzer, K W Kelley.   

Abstract

Leukocytes synthesize a variety of hormones that were once thought to be unique products of endocrine tissues. Understanding the regulation of leukocyte-derived hormone synthesis requires an accurate means for measuring steady-state expression of specific mRNA transcripts. Here we describe a competitive reverse transcriptase-polymerase chain reaction (RT-PCR) technique to accurately quantitate macrophage-derived insulin-like growth factor-I (IGF-I) mRNA, and demonstrate the utility of this approach for measuring expression of leukocyte-derived hormone transcripts. A riboprobe was constructed to generate approximately 1 kb of synthetic competitor IGF-I RNA (exons 1 and 3-6) that differed from cellular IGF-I RNA by insertion of 122 bp of beta-actin RNA. One set of oligonucleotide primers could thus be used to simultaneously reverse transcribe and amplify both 144 bp of cellular (exons 3 and 4) and 266 bp of competitor IGF-I RNA. Densitometric scanning of the PAGE-separated PCR products revealed that the ratio of competitor to cellular amplified DNA bore a linear relationship (r2 > or = 0.98) to the amount of competitor RNA for both rat liver and splenocytes. However, rat liver contained 104 x 10(6) IGF-I molecules per microgram of total cellular RNA compared to only 2 x 10(6) IGF-I molecules for splenocytes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8528883     DOI: 10.1159/000097088

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  1 in total

1.  Constitutive and regulated expression of the class IB molecule Qa-1 in pancreatic beta cells.

Authors:  T Chun; C J Aldrich; M E Baldeón; L V Kawczynski; M J Soloski; H R Gaskins
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.